Advances in Clinical Trials: Outcome, Innovations, Challenges, and Ethical Practice in Cancer Research 2024–2025

Dear Colleagues,

Welcome to this Special Issue. We are at the forefront of an era that greatly values the dissemination of clinical trial outcomes of all phase studies (phase I, phase II, phase III, and phase IV), recognizing the profound impact of shared knowledge on the advancement of medical science. In this spirit, we encourage you to publish your findings, understanding that each piece of data, whether from trials that have met their endpoints or those that have not, propels us closer to scientific breakthroughs.

This Special Issue is committed to unraveling clinical trials' complexities and dynamic nature. Our objective is to thoroughly analyze their contemporary features, their design and implementation, and how they contribute to the forward momentum of medical research. We seek contributions in the form of original research, editorial insights, and comprehensive reviews that highlight innovative clinical trial outcomes.

We will spotlight pioneering methodologies that set new precedents in clinical research, including adaptive designs, patient-centered strategies, and the seamless incorporation of technology into trial management. Our readers will gain an intricate understanding of these methods in practice, the guiding regulatory frameworks, and the ethical pillars at their heart.

Moreover, we advocate for sharing all cancer clinical trial results openly. Regardless of their nature, each result significantly enriches our collective wisdom and influences the future path of scientific inquiry.

We invite you to share your experiences of success and the challenges faced during the execution of modern clinical trials. Your insights are invaluable in shaping the future of clinical research. Together, we strive to create a collaborative platform that fosters the development of treatments with a meaningful impact on our cancer community.

Mahalo for your unwavering commitment to advancing our understanding of this critical aspect of cancer clinical trials.

Prof. Dr. Naoto T. Ueno
Prof. Dr. David R. Gandara
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• phase I
• phase II
• phase III
• phase IV
• clinical trials
• features
• design
• implementation
• outcomes